Purinergic signaling in Parkinson’s disease (2023)
- Authors:
- USP affiliated authors: ULRICH, ALEXANDER HENNING - IQ ; BRITTO, LUIZ ROBERTO GIORGETTI DE - ICB ; SILVA, JEAN BEZERRA - IQ ; FERREIRA, ANA FLAVIA FERNANDES - ICB ; GLASER, TALITA - IQ
- Unidades: IQ; ICB
- Assunto: DOENÇA DE PARKINSON
- Language: Inglês
- Imprenta:
- Source:
- Título: Purinergic signaling in neurodevelopment, neuroinflammation and neurodegeneration
- Volume/Número/Paginação/Ano: 376 p
-
ABNT
SILVA, Jean Bezerra et al. Purinergic signaling in Parkinson’s disease. Purinergic signaling in neurodevelopment, neuroinflammation and neurodegeneration. Tradução . Cham: Springer, 2023. . . Acesso em: 11 fev. 2026. -
APA
Silva, J. B., Ferreira, A. F. F., Glaser, T., Ulrich, H., & Britto, L. R. G. de. (2023). Purinergic signaling in Parkinson’s disease. In Purinergic signaling in neurodevelopment, neuroinflammation and neurodegeneration. Cham: Springer. -
NLM
Silva JB, Ferreira AFF, Glaser T, Ulrich H, Britto LRG de. Purinergic signaling in Parkinson’s disease. In: Purinergic signaling in neurodevelopment, neuroinflammation and neurodegeneration. Cham: Springer; 2023. [citado 2026 fev. 11 ] -
Vancouver
Silva JB, Ferreira AFF, Glaser T, Ulrich H, Britto LRG de. Purinergic signaling in Parkinson’s disease. In: Purinergic signaling in neurodevelopment, neuroinflammation and neurodegeneration. Cham: Springer; 2023. [citado 2026 fev. 11 ] - Neurodegeneration and glial morphological changes are both prevented by TRPM2 inhibition during the progression of a Parkinson's disease mouse model
- Deletion of the transient receptor potential Melastatin 2 gene mitigates the 6-hydroxydopamine-induced parkinson’s disease–like pathology
- Deletion of the transient receptor potential melastatin 2 gene mitigates the 6-hyydroxydopamine-induced Parkinson’s Disease–Like Pathology
- The role of interleukin-17 in neurological disorders
- Inhibition of neuroinflammation by GIBH-130 (AD-16) reduces neurodegeneration, motor deficits, and proinflammatory cytokines in a hemiparkinsonian model
- The transient receptor potential melastatin 2: a new therapeutical target for Parkinson’s disease?
- Inhibition of TRPM2 by AG490 is neuroprotective in a Parkinson’s Disease animal model
- Adenosinergic-dopaminergic signaling in mood disorders: a mini-review
- Huntingtin protein maintains balanced energetics in mouse cardiomyocytes
- Ginkgolides and Huperzine A for complementary treatment of Alzheimer's disease
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
